Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Isotechnika -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (82)	6/9/2003 11:20:27 AM
From: schzammm	Respond to of 285

Icebrg, thanks for your many informative posts. ISA is knocking on the door of a tecnical breakout. Difficult to know if Isa is just getting pulled along with the sector or if the the price rise is company specific. stockcharts.com

To: Icebrg who wrote (82)	6/11/2003 5:35:27 AM
From: Icebrg	Read Replies (1) \| Respond to of 285

Isotechnika/Roche's ISA247 comparable to cyclosporine for kidney transplant patients [The following is from SG Cowen's PharmaCare Update. Although the snip doesn't give any new information, it is perhaps an indication that Isotechnika's profile has been raised and that they are starting to be noticed. Erik] A Phase IIa study presented at the American Transplant Congress conducted by Isotechnika of the company's immunosuppressive drug ISA247 (novel calcineurin inhibitor co-developed with Roche) in stable kidney transplant patients showed that ISA247 is effective and well tolerated. Stable kidney transplant patients on ISA247 achieved a level of immunosuppression comparable to patients given cyclosporine at one third the blood drug concentration. Early studies indicate that ISA247 is onsiderably more potent and less toxic compared to other immunosuppressants, such as cyclosporine A. This powerful combination of reduced toxicity and improved potency should provide a major therapeutic benefit over existing calcineurin based regimens.